|
KMID : 1001020210190010030
|
|
Journal of Urologic Oncology
2021 Volume.19 No. 1 p.30 ~ p.39
|
|
|
The Development of Antibody-Drug Conjugates for Urothelial Carcinoma Treatment
|
|
Choi Da-Som
Kang Su-Jeong
Chang In-Ho
Choi Young-Wook
|
|
|
Abstract
|
|
|
|
Urothelial cancer is the seventh most common cancer among men worldwide. Bacille de Calmette-Guerin is a type of anticancer immunotherapy that has been used to treat targeted bladder cancer, but the number of patients with treatment-refractory advanced urothelial cancer, patients has been increasing recently. To overcome this, enfortumab vedotin (novel nectin-4 targeting antibody-drug conjugate) known as antibody-drug conjugate (ADC), was approved. We describe the clinical development process of ADC and the potential for future development as a bladder cancer treatment.
|
|
|
KEYWORD
|
|
|
Antibody-drug conjugate, HER2, Immunotherapy, Nectin-4, Urothelial carcinoma
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|